Our central policy goal is for the UK to recognise healthy life extension as a national priority. From that goal flow six practical areas: ageing research, clinical translation and patient access, biotech growth, fair access, cultural change, and preservation choice.

The UK should adopt healthy life extension as a national objective: not merely helping people age better within current limits, but actively working towards much longer, healthier lives. This should guide research funding, NHS prevention, regulation, industrial strategy, public health and long-term planning.

Biology of ageing research

The UK should substantially increase funding for research into the biology of ageing and the mechanisms that drive age-related disease, including the hallmarks of ageing, immune ageing, cellular senescence, epigenetic change, mitochondrial dysfunction, stem cell exhaustion and loss of tissue repair. Without deeper understanding of ageing, first-generation interventions will remain limited.

Clinical trials, regulation and right to try

The UK should develop clearer clinical trial and regulatory pathways for interventions that target ageing processes, rather than forcing every therapy into a single-disease model. This should include better biomarkers, surrogate endpoints, adaptive trials, prevention-focused trial designs, regulatory guidance for geroprotective and rejuvenation therapies, and a UK-appropriate “right to try” discussion for people who want access to promising investigational treatments when conventional options are limited.

UK longevity biotech

The UK should aim to become a leading global centre for longevity biotechnology and rejuvenation medicine, supporting university spin-outs, translational research, patient capital, specialist incubators, manufacturing, clinical trial infrastructure and international partnerships. Life extension should be treated as a strategic scientific and economic opportunity.

Equal access

Future life-extension medicine should not be available only to the wealthy. The UK should plan early for fair access through the NHS, public funding, inclusive trials, fair pricing, and policies that reduce rather than widen existing inequalities in healthy life expectancy. The goal should be longer, healthier lives for everyone who wants them.

Anti-ageism and anti-fatalism

Public policy should challenge the assumption that frailty, dementia, disability and chronic disease are simply inevitable parts of ageing. LFS should oppose ageism while also opposing fatalism about age-related decline: older people should be valued today, while science works to prevent the suffering currently associated with ageing.

Cryonics and preservation choice

People who want cryopreservation should have clearer legal rights and practical support to make that choice. The UK should recognise cryonics as a legitimate preservation option for people who see it as a continuation of patient care, clarify consent and advance instruction rules, improve procedures at the point of legal death, protect families and medical professionals acting in good faith, regulate providers transparently, and review whether terminally ill people with capacity should have expanded rights to cryopreservation planning before legal death.